An interventional study of Transcranial direct current stimulation and Sham transcranial direct current stimulation in Major Depressive Disorder (MDD), sponsored by Sooma Medical Inc. Recruiting at 1 site in United States. Open to participants aged 22 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-14.
Sponsored by Sooma Medical Inc · Not applicable, Interventional, and Treatment
The REACH-tDCS study will evaluate the safety and efficacy of a noninvasive, at-home self-administered Sooma tDCS brain stimulation treatment for Major Depressive Disorder. The study uses randomized, blinded, placebo controlled design. The participants are assessed with video interviews and self-reports during the study, which lasts for 10 weeks followed by an optional continuation period.
The study stages include: screening, eligibility evaluation, randomization to active or sham arm (1:1), the first treatment period (weeks 1-10) with sham-control and the optional open-label phase (weeks 11-20) where all treatments will be in active mode.
2,741 studies on the registry are indexed under Depressive Disorder, Major; 559 are open to participants now.
This study's planned enrollment of 200 is above the median of 80 across 2,283 interventional studies indexed under Depressive Disorder, Major.
Browse Depressive Disorder, Major studies →This is the only study on the registry with Sooma Medical Inc as lead sponsor.
Counted across the registry records on this site, refreshed daily.
In short,
Inclusion Criteria:
Exclusion Criteria:
Device: Transcranial direct current stimulation
Device: Sham transcranial direct current stimulation
In tDCS treatment session electrical current (2 mA) is applied for 30 minutes through two electrodes placed on top of scalp to modulate neural activity.
Sham treatment mimics the active device use and the experiences from the active stimulation while minimizing active effects.
MADRS: change from baseline
Mean change in depressive symptoms, measured by the Montgomery-Asberg Depression Rating Scale (MADRS) total score, from baseline to week 10. MADRS ranges from 0 to 60, with higher scores indicating more severe depression.
Time frame: 10 weeks from treatment initiation.
MADRS: rate of response
Rate of response defined as the percent of subjects achieving at least 50% reduction from baseline in their MADRS at week 10.
Time frame: 10 weeks from treatment initiation.
MADRS: rate of remission
Rate of remission remission defined as the percent of subjects with MADRS score ≤ 10 at week 10.
Time frame: 10 weeks from treatment initiation.
HAM-D17: change form baseline
Mean change in depressive symptoms, measured by Hamilton Depression Rating Scale (17-items) (HAM-D17), from baseline to week 10. HAM-D17 ranges from 0 to 52, with higher scores indicating more severe depression.
Time frame: 10 weeks from treatment initiation.
HAM-D17: rate of response
Rate of response defined as the percent of subjects achieving at least 50% reduction from baseline in their HAM-D17 at week 10.
Time frame: 10 weeks from treatment initiation.
HAM-D17: rate of remission
Rate of remission defined as the percent of subjects with HAM-D17 score ≤ 7 at week 10.
Time frame: 10 weeks from treatment initiation.
PHQ-9: change from baseline
Mean change in depressive symptoms, measured by Patient Health Questionnaire-9 (PHQ-9) total score, from baseline to week 10. PHQ-9 ranges from 0 to 27, with higher scores indicating more severe depression.
Time frame: 10 weeks from treatment initiation.
PHQ-9: rate of response
Rate of response defined as the percent of subjects achieving at least 50% reduction from baseline in their PHQ-9 at week 10.
Time frame: 10 weeks from treatment initiation.
PHQ-9: rate of remission
Rate of remission, defined as the percent of subjects with PHQ-9 score ≤ 4 at week 10.
Time frame: 10 weeks from treatment initiation.
CGI-I
The clinical global impression - improvement scale (CGI-I) is a 7-point scale allowing the clinical rater to assess how much the patient's overall condition has improved or worsened since starting the intervention (1. very much improved, 2. much improved, 3. minimally improved, 4. no change, 5. minimally worse, 6. much worse, 7. very much worse).
Time frame: 10 weeks from treatment initiation.
Plan to share: Yes — The IPD used in the results of the publication will be shared.
Supporting information: Study protocol, Analytic code
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.